文献速递新发突发、热带与寄生虫病

布基纳法索和马里5岁以下儿童季节性接种RTS,S/AS01E疫苗联合或不联合季节性疟疾化学预防:双盲、随机、对照3期试验

Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Infect Dis · 2023-08-22

在布基纳法索和马里两中心开展双盲、个体随机、对照3期试验,评价季节性RTS,S/AS01E疫苗接种联合季节性疟疾化学预防(SMC)在5岁以下儿童中5年内的保护作用。5年临床疟疾发病率在单用SMC组为313/1000人年、单用RTS,S/AS01E组为320/1000人年、联合组为133/1000人年;联合较SMC的保护效力为57·7%(95%CI 53·3~61·7),联合较单用RTS,S/AS01E为59·0%(54·7~62·8),RTS,S/AS01E非劣于SMC。

要点

  • 联合组5年临床疟疾发病率为133/1000人年,低于单用SMC组的313和单用RTS,S/AS01E组的320。
  • 联合较SMC的保护效力57·7%(95%CI 53·3~61·7),联合较单用RTS,S/AS01E为59·0%(54·7~62·8)。
  • 联合组较单用SMC组WHO定义重症疟疾住院减少66·8%(95%CI 40·3~81·5),未发现安全性信号。

核心结论

  • 季节性疟疾疫苗接种联合季节性化学预防在5年内持续提供对疟疾的实质性保护,为季节性疟疾传播地区的疟疾控制提供了潜在新途径。

研究设计与样本

  • 双盲、个体随机、对照、非劣效与优效性3期试验,在布基纳法索Houndé区和马里Bougouni区及邻近地区两中心开展。
  • 初始3年试验中5~17月龄入组儿童随机接受SMC(磺胺多辛-乙胺嘧啶加阿莫地喹)加对照疫苗、RTS,S/AS01E加安慰剂SMC、或SMC加RTS,S/AS01E,并继续至5岁。
  • 主要终点为5年试验期间临床疟疾发病率,在改良意向治疗和符合方案人群中分析。
  • 5年期间非劣效定义为单用RTS,S/AS01E组较单用SMC组临床疟疾增加20%,优效定义为联合组与单干预组临床疟疾发病率相差12%。
  • 2020年4月,最初入组6861名儿童中,完成初始3年随访的5433名儿童有5098名(94%)重新入组扩展研究。

主要发现

  • 5年临床疟疾每1000人年发病率:单用SMC组313、单用RTS,S/AS01E组320、联合组133。
  • 联合较SMC的 protective efficacy 为57·7%(95%CI 53·3~61·7),联合较单用RTS,S/AS01E为59·0%(54·7~62·8)。
  • RTS,S/AS01E非劣于SMC(HR 1·03,95%CI 0·95~1·12)。
  • 前3年联合较SMC的保护效力为62·8%(58·4~66·8),联合较单用RTS,S/AS01E为59·6%(54·7~64·0%)。
  • 联合组较单用SMC组:WHO定义重症疟疾住院减少66·8%(95%CI 40·3~81·5),疟疾性贫血住院减少65·9%(34·1~82·4),输血减少68·1%(32·6~84·9),全因死亡减少44·5%(2·8~68·3),排除外因或手术的死亡减少41·1%(-9·2~68·3),疟疾死亡减少66·8%(-2·7~89·3)。

关键数值与推荐

  • 非劣效界值:5年期间单用RTS,S/AS01E组较单用SMC组临床疟疾增加20%。
  • 优效界值:联合组与单干预组临床疟疾发病率相差12%。
  • 联合较SMC的保护效力57·7%(95%CI 53·3~61·7),联合较单用RTS,S/AS01E为59·0%(54·7~62·8)。
  • RTS,S/AS01E较SMC的HR 1·03(95%CI 0·95~1·12)。

临床怎么用

  • 作者认为,季节性疟疾疫苗接种联合季节性化学预防在5年内持续提供实质性保护,为季节性疟疾传播地区的疟疾控制提供了潜在新途径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Seasonal vaccination with the RTS,S/AS01E vaccine combined with seasonal malaria chemoprevention (SMC) prevented malaria in young children more effectively than either intervention given alone over a 3 year period. The objective of this study was to establish whether the added protection provided by the combination could be sustained for a further 2 years. METHODS: This was a double-blind, individually randomised, controlled, non-inferiority and superiority, phase 3 trial done at two sites: the Bougouni district and neighbouring areas in Mali and Houndé district, Burkina Faso. Children who had been enrolled in the initial 3-year trial when aged 5-17 months were initially randomly assigned individually to receive SMC with sulphadoxine-pyrimethamine and amodiaquine plus control vaccines, RTS,S/AS01E plus placebo SMC, or SMC plus RTS,S/AS01E. They continued to receive the same interventions until the age of 5 years. The primary trial endpoint was the incidence of clinical malaria over the 5-year trial period in both the modified intention-to-treat and per-protocol populations. Over the 5-year period, non-inferiority was defined as a 20% increase in clinical malaria in the RTS,S/AS01E-alone group compared with the SMC alone group. Superiority was defined as a 12% difference in the incidence of clinical malaria between the combined and single intervention groups. The study is registered with ClinicalTrials.gov, NCT04319380, and is complete. FINDINGS: In April, 2020, of 6861 children originally recruited, 5098 (94%) of the 5433 children who completed the initial 3-year follow-up were re-enrolled in the extension study. Over 5 years, the incidence of clinical malaria per 1000 person-years at risk was 313 in the SMC alone group, 320 in the RTS,S/AS01E-alone group, and 133 in the combined group. The combination of RTS,S/AS01E and SMC was superior to SMC (protective efficacy 57·7%, 95% CI 53·3 to 61·7) and to RTS,S/AS01E (protective efficacy 59·0%, 54·7 to 62·8) in preventing clinical malaria. RTS,S/AS01E was non-inferior to SMC (hazard ratio 1·03 [95% CI 0·95 to 1·12]). The protective efficacy of the combination versus SMC over the 5-year period of the study was very similar to that seen in the first 3 years with the protective efficacy of the combination versus SMC being 57·7% (53·3 to 61·7) and versus RTS/AS01E-alone being 59·0% (54·7 to 62·8). The comparable figures for the first 3 years of the study were 62·8% (58·4 to 66·8) and 59·6% (54·7 to 64·0%), respectively. Hospital admissions for WHO-defined severe malaria were reduced by 66·8% (95% CI 40·3 to 81·5), for malarial anaemia by 65·9% (34·1 to 82·4), for blood transfusion by 68·1% (32·6 to 84·9), for all-cause deaths by 44·5% (2·8 to 68·3), for deaths excluding external causes or surgery by 41·1% (-9·2 to 68·3), and for deaths from malaria by 66·8% (-2·7 to 89·3) in the combined group compared with the SMC alone group. No safety signals were detected. INTERPRETATION: Substantial protection against malaria was sustained over 5 years by combining seasonal malaria vaccination with seasonal chemoprevention, offering a potential new approach to malaria control in areas with seasonal malaria transmission. FUNDING: UK Joint Global Health Trials and PATH's Malaria Vaccine Initiative (through a grant from the Bill & Melinda Gates Foundation). TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dicko A, Ouedraogo JB, Zongo I, et al. Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. Lancet Infect Dis. 2023. PMID: 37625434. doi:10.1016/S1473-3099(23)00368-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。